EFTA02617028.pdf
dataset_11 pdf 291.4 KB • Feb 3, 2026 • 6 pages
From: Boris Nikolic <
Sent: Saturda , November 3, 2018 11:15 PM
To:
Cc: jeevacation@gmail.com
Subject: RE: Re:
Hi Harry
Please let me double check this.
There are many projects that BMGF specifically do not fund directly (especially if it has to do with a delivery,
procurement etc) but through partners such as PATH, PSI etc.
There are some projects that BMGF funded a lot such a male circumcision but got eventually transferred to the partners.
It will take me few days to find out as I do not know the new director of Reproductive Health (they changed few since I
left!) and strangely RH is a part of global development (not a Global Health).
Please ping me in a week or so.
Best
Boris
From:
Sent: Saturday, November 3, 2018 2:32 PM
To: Boris Nikolic <
Cc: jeevacation@gmail.com
Subject: Re:
Hi Boris
Currently The Female Health division of VERU supplies approximately SO million Female Condoms worldwide. BMGF has
never funded the FC2 Female condom. I don't know why this is the case.
EFTA_R1_01818211
EFTA02617028
The FC2 female condom is the most demanded and utilized female condom worldwide. It is supplied throughout Africa
via UNFPA and bought directly by South Africa.
Funding by UNFPA has dramatically decreased and we are unable to supply certain countries that have requested the
female condom.
For example, the following countries have requested the FC2 female condom but we are unable to supply:
Uganda : 3 million units
Ghana: 1 million units
Botswana: 1 million units
Tunesia: 1 million units
Sierra Leone: 500,000 units
Bolivia: 500,000 units
Tanzania: 1 million units
Haiti: 500,000 units
Ethiopia: 1 million units
Congo DR: 2 million units
Boris, can you introduce me to the right person at BMGF to see if we can get grants to provide FC2 female condoms to
all women who request them in Africa.
Also attached is more information regarding the FC2 female condom.
Would like to continue the conversation.
Sincerely,
Harry
2
EFTA_R1_01818212
EFTA02617029
Original Message
From: Boris Nikolic < <mailto >>
To: harryfisch < <mailto >>
>
Cc: jeevacation <jeevacation@gmail.com <mailto:jeevacation@gmail.com»
Sent: Sat, Nov 3, 2018 1:27 pm
Subject: RE: Re:
Thank you Harry!
Again — great meeting you. I am still laughing re inherited STD.
Finally I had chance to read your slide deck. VERU is indeed very interesting company — congrats!
You have an interesting mix of Urology specialty drugs (which I see as a low risk) and Prostate cancer drugs.
Unfortunately my fund (https://www.biomaticscapital.com/) is only focused (and restricted to investing) on private
companies.
Mid-end of the next year I am going to fundraise a crossover fund which would allow me to invest in both private and
publicly listed companies; nevertheless, I am now unable to invest in companies such as VERU — despite how interesting
they might be.
I looked at a female condom. I think that PATH supported a number of related projects.
https://www.path.oreartides/seven-secrets-of-the-female-condom/ <https://www.path.org/articles/seven-secrets-of-
the-female-condomh
As you might know BMGF is the main donor to PATH — this is why I mentioned it.
Also BMGF founded several smaller grants (GCE) re female condoms https://www.gatesfoundation.org/Media-
Center/Press-Releases/2014/06/GCE-Round-12 <https://www.gatesfoundation.org/Media-Center/Press-
Releases/2014/06/GCE-Round-12>
In addition, there were grants to Imperial College in London, HealthRock etc.
All of these are relatively old grants that ended. My guess is that all female condom more mature projects transitioned
to PATH.
Also I see that PSI has been funding marketing and delivery https://www.psi.org/2018/03/fresh-start-female-condom-
marketing/ <https://www.psi.org/2018/03/fresh-start-female-condom-marketing/>
3
EFTA_R1_01818213
EFTA02617030
Please let me know if there is anything else I can be of help to you.
Hope to see you soon in NYC
Best
Boris
From: <mailto > < <mailto >>
Sent: Thursday, November 1, 2018 5:34 PM
To: Boris Nikolit < <mailto >>;
jeevacation@gmail.com <mailto:jeevacation@gmail.com>
Subject: Re:
Jeffrey thanks for introducing me to Boris.
Boris, great meeting you as well.
Attached is the most recent deck for VERU (NASDAQ: VERU), www.verupharma.com <http://www.verupharma.com> .
In addition please look at www.femalecondom.com <http://www.femalecondom.com> . We merged with The Female
Health Company which sells the FC2 Female Condom to the public sector in Africa and Brazil via UNFPA and USAID. We
just recently introduced this condom into the US market mainly via telemedicine.
Would love to meet and discuss further.
Sincerely,
4
EFTA_R1_01818214
EFTA02617031
Harry
Harry Fisch MD
cell
Original Message
From: Boris Nikolic < <mailto >>
To: .1 <jeevacation@gmail.com <mailto:jeevacation@gmail.com»; Harry Fisch <
<mailto: >
Sent: Thu, Nov 1, 2018 4:13 pm
Subject: RE:
Thank you J!
Great meeting you Harry!
Looking forward to seeing you again.
Please send me something re your company.
Best
Boris
From: J <jeevacation@gmail.com <mailto:jeevacation@gmail.com»
Sent: Thursday, November 1, 2018 3:15 PM
To: Boris Nikolic < <mailto »; Harry Fisch
<mailto-> >
Subject:
harry boris , boris harry
please note
The information contained in this communication is
5
EFTA_R1_01818215
EFTA02617032
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation@gmail.com <mailtcyjeevacation@gmail.com> , and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
6
EFTA_R1_01818216
EFTA02617033
Entities
0 total entities mentioned
No entities found in this document
Document Metadata
- Document ID
- 01951282-4b97-451b-a8e2-9d4269282088
- Storage Key
- dataset_11/EFTA02617028.pdf
- Content Hash
- bda92dd5a86f8db4165e60b498213b23
- Created
- Feb 3, 2026